Jeff Bezos Is Funding a Wild Hunt for the Brain’s ‘Core Algorithm’

With $500 million in funding and a reported $2.5 billion valuation, Flourish wants to reinvent AI by putting real neurons ...
Scientific American

New protein-folding AI predicts the structures of 1 billion proteins

The new open-source atlas, generated by an AI tool called ESMFold2, vastly increases the known protein universe ...
PBS

How online retailers are using AI to adjust prices by mining your personal data

If you’re going online to buy some last-minute gifts this holiday season, there’s a chance the price you pay will be influenced by what’s known as “surveillance pricing.” Some retailers are using ...
Seeking Alpha

Recursion: "Hold" Rating Based On Initial REC-4881 FAP Treatment Data

The last time I wrote about Recursion Pharmaceuticals (RXRX), it was with respect to a Seeking Alpha article entitled "Recursion: CDK7 Differentiation Is Initially Paying Off." With respect to this ...
STAT

Merck’s RSV drug approval and a drug manufacturer winds down

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...
Nasdaq

MIT and Recursion Unveil Boltz-2: A Revolutionary Open-Source Biomolecular Co-Folding Model with Advanced Structure and Binding Affinity Prediction

Boltz-2 is an open-source biomolecular model achieving near-FEP accuracy with 1000x faster predictions for structure and binding affinity. MIT and Recursion have released Boltz-2, the first ...
Insider Monkey

Recursion Pharmaceuticals, Inc. (RXRX): The Best Performing Pharma Stock So Far in 2025?

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against ...
BioSpace

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Met primary endpoint of safety and tolerability in CCM patients with no treatment-related discontinuations or Grade 3 adverse events In comparison to placebo, treatment with REC-994 400 mg showed ...
STAT

Summit’s upcoming cancer results, Recursion’s mixed data, and a new co-host

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...
TMCnet

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of ...

SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced top-line results of ...
AOL

Nvidia-backed Recursion's shares fall on mixed data for rare disorder drug

(Reuters) -Nvidia-backed Recursion Pharmaceuticals said on Tuesday its experimental drug to treat a rare brain-related condition was safe and tolerable in a mid-stage study, but showed mixed results ...